Literature DB >> 23323150

Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.

Maarten J Deenen1, Annemieke Cats, Jos H Beijnen, Jan H M Schellens.   

Abstract

Entities:  

Year:  2013        PMID： 23323150      PMCID： PMC3539277          DOI： 10.1177/1758834012464806

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


× No keyword cloud information.
  9 in total

1.  Standard-dose tegafur combined with uracil is not safe treatment after severe toxicity from 5-fluorouracil or capecitabine.

Authors:  Maarten J Deenen; Wim E Terpstra; Annemieke Cats; Henk Boot; Jan H M Schellens
Journal:  Ann Intern Med       Date:  2010-12-07       Impact factor: 25.391

2.  Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.

Authors:  T Shirasaka; K Nakano; T Takechi; H Satake; J Uchida; A Fujioka; H Saito; H Okabe; K Oyama; S Takeda; N Unemi; M Fukushima
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

3.  Suicidal inactivation of human dihydropyrimidine dehydrogenase by (E)-5-(2-bromovinyl)uracil derived from the antiviral, sorivudine.

Authors:  K Ogura; T Nishiyama; H Takubo; A Kato; H Okuda; K Arakawa; M Fukushima; S Nagayama; Y Kawaguchi; T Watabe
Journal:  Cancer Lett       Date:  1998-01-09       Impact factor: 8.679

4.  The uracil breath test in the assessment of dihydropyrimidine dehydrogenase activity: pharmacokinetic relationship between expired 13CO2 and plasma [2-13C]dihydrouracil.

Authors:  Lori K Mattison; Jeanne Fourie; Yukihiro Hirao; Toshihisa Koga; Renee A Desmond; Jennifer R King; Takefumi Shimizu; Robert B Diasio
Journal:  Clin Cancer Res       Date:  2006-01-15       Impact factor: 12.531

5.  Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators.

Authors:  T Shirasaka; Y Shimamato; H Ohshimo; M Yamaguchi; T Kato; K Yonekura; M Fukushima
Journal:  Anticancer Drugs       Date:  1996-07       Impact factor: 2.248

6.  Tegafur-uracil is a safe alternative for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.

Authors:  Daniel I G Cubero; Felipe Melo Cruz; Patrícia Santi; Ismael Dale C G Silva; Auro Del Giglio
Journal:  Ther Adv Med Oncol       Date:  2012-07       Impact factor: 8.168

7.  A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs.

Authors:  H Okuda; K Ogura; A Kato; H Takubo; T Watabe
Journal:  J Pharmacol Exp Ther       Date:  1998-11       Impact factor: 4.030

8.  Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.

Authors:  D H Ho; R Pazdur; W Covington; N Brown; Y Y Huo; Y Lassere; J Kuritani
Journal:  Clin Cancer Res       Date:  1998-09       Impact factor: 12.531

9.  Alternative pharmacokinetics of S-1 components, 5-fluorouracil, dihydrofluorouracil and alpha-fluoro-beta-alanine after oral administration of S-1 following total gastrectomy.

Authors:  Woo Young Kim; Bunzo Nakata; Kosei Hirakawa
Journal:  Cancer Sci       Date:  2007-08-07       Impact factor: 6.716
  9 in total
  1 in total

1.  Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle.

Authors:  Daniel I G Cubero; Auro Del Giglio
Journal:  Ther Adv Med Oncol       Date:  2013-01       Impact factor: 8.168
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.